CN112175899A - Mesenchymal stem cell osteogenic directional differentiation inducing liquid and application thereof - Google Patents
Mesenchymal stem cell osteogenic directional differentiation inducing liquid and application thereof Download PDFInfo
- Publication number
- CN112175899A CN112175899A CN201910598597.7A CN201910598597A CN112175899A CN 112175899 A CN112175899 A CN 112175899A CN 201910598597 A CN201910598597 A CN 201910598597A CN 112175899 A CN112175899 A CN 112175899A
- Authority
- CN
- China
- Prior art keywords
- mesenchymal stem
- stem cell
- differentiation inducing
- inducing liquid
- osteogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 100
- 230000001939 inductive effect Effects 0.000 title claims abstract description 64
- 230000004069 differentiation Effects 0.000 title claims abstract description 61
- 239000007788 liquid Substances 0.000 title claims abstract description 54
- 230000002188 osteogenic effect Effects 0.000 title claims abstract description 44
- 210000001808 exosome Anatomy 0.000 claims description 37
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 12
- 210000001185 bone marrow Anatomy 0.000 claims description 9
- 239000001963 growth medium Substances 0.000 claims description 9
- 210000000963 osteoblast Anatomy 0.000 claims description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 8
- 229930182555 Penicillin Natural products 0.000 claims description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 7
- 229960005070 ascorbic acid Drugs 0.000 claims description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 7
- 229960003957 dexamethasone Drugs 0.000 claims description 7
- 229940049954 penicillin Drugs 0.000 claims description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims description 6
- 239000011668 ascorbic acid Substances 0.000 claims description 6
- 239000012091 fetal bovine serum Substances 0.000 claims description 6
- AVPCPPOOQICIRJ-UHFFFAOYSA-L sodium glycerol 2-phosphate Chemical compound [Na+].[Na+].OCC(CO)OP([O-])([O-])=O AVPCPPOOQICIRJ-UHFFFAOYSA-L 0.000 claims description 6
- 229960005322 streptomycin Drugs 0.000 claims description 6
- 239000012228 culture supernatant Substances 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 description 15
- 230000009818 osteogenic differentiation Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 230000011164 ossification Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 230000017423 tissue regeneration Effects 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000003954 umbilical cord Anatomy 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000004072 osteoblast differentiation Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012258 culturing Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108091070501 miRNA Proteins 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229960002901 sodium glycerophosphate Drugs 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- -1 antigen presentation Proteins 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940112869 bone morphogenetic protein Drugs 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1369—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides a mesenchymal stem cell osteogenic directional differentiation inducing liquid and application thereof.
Description
Technical Field
The present invention belongs to the field of regenerative medicine. In particular to mesenchymal stem cell osteogenic directional differentiation inducing liquid and a preparation method and application thereof.
Background
The mesenchymal stem cells are ideal seed cells for repairing damaged tissues due to the self-renewal and multidirectional differentiation capacity. The directional induced differentiation of the mesenchymal stem cells can provide a new technical method for clinically treating tissue diseases and tissue defects. However, mesenchymal stem cells can be differentiated into other types of cells as well as the desired tissue cells and participate in tissue repair. Therefore, there is a need to regulate the differentiation of mesenchymal stem cells to allow directed differentiation into desired tissue cells or precursor cells. Improving the directional differentiation efficiency, reducing the differentiation capability of the mesenchymal stem cells to other types of cells in vivo, and improving the tissue treatment and repair effects. At present, the traditional method for inducing mesenchymal stem cells to differentiate generally uses chemical inducing molecules to induce mesenchymal stem cells to differentiate directionally. Such as dexamethasone or bone morphogenetic protein, can induce the mesenchymal stem cells to differentiate into osteoblasts.
Exosomes (exosomes) are micro-vesicles produced by the exocrine of cellular endosomes, with diameters between 40-100 nm. Microvesicles play an important role in signal communication between cells through interaction with target cell-associated receptors and transfer of proteins, mRNA, miRNA, DNAs, lipids, etc. It has been found that exosomes can be derived from various types of cells, such as B cells, T cells, dendritic cells, tumor cells, stem cells, endothelial cells, etc., and can produce different effects, such as clearance of nonfunctional proteins, antigen presentation, gene exchange, vascular proliferation, promotion of differentiation, inflammation, tumor metabolism, transmission of pathogenic or oncogenes, etc., and the effects of exosomes are generally consistent with the physiological properties of the cells from which they are derived.
As a bridge for transferring functional substances between adjacent cells, exosomes are increasingly gaining attention in the microenvironment of cell-cell interaction. In recent years, research on mesenchymal stem cells has been gradually expanded to research on the function of secreted exosomes, for example, exosomes secreted by mesenchymal stem cells contribute to the shift of the microenvironment of organ tissues from inflammatory to anti-inflammatory under injury stress conditions, and can promote fracture healing, regeneration of cardiomyocytes and chondrocytes, and the like. Based on the characteristics of the low-immunogenicity carrier (capable of transmitting genetic control substances such as miRNA, siRNA and the like), the mesenchymal stem cell has attractive prospect in the aspect of mesenchymal stem cell differentiation. Research has shown that dendritic cell exosome can induce the differentiation of mesenchymal stem cells into osteogenesis; the exosome derived from the human original mononuclear cell after lipopolysaccharide treatment has a certain effect of promoting the osteogenic differentiation of the mesenchymal stem cell. In the process of repairing bone defects, mesenchymal stem cells derived from bone marrow play an important role. Research shows that the bone marrow mesenchymal stem cells can promote bone regeneration, and exosomes derived from the bone marrow mesenchymal stem cells have the effect of promoting proliferation and differentiation of osteoblasts.
The traditional method for inducing mesenchymal stem cell differentiation generally uses chemical inducing molecules to induce mesenchymal stem cell differentiation directionally, but the inducing time is 3-4 weeks, the required time is too long, and the amount of calcium nodules is relatively small.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides the mesenchymal stem cell osteogenic directional differentiation inducing liquid and the application thereof.
The purpose of the invention is realized by the following technical scheme:
the invention provides mesenchymal stem cell osteogenic directional differentiation inducing liquid, which comprises the following components: culture medium and exosomes.
Preferably, the culture substrate is an α -MEM medium.
Preferably, the exosome is prepared from a culture supernatant of mesenchymal stem cells, and the final concentration of the exosome is 5-10 mg/L. For example: 5mg/L, 6mg/L, 7mg/L, 8mg/L, 9mg/L, or 10 mg/L.
Preferably, the mesenchymal stem cell osteogenic directed differentiation inducing liquid further comprises fetal bovine serum, and the volume ratio of the fetal bovine serum is 5-10%. For example: 5%, 6%, 7%, 8%, 9% or 10%.
Preferably, the mesenchymal stem cell osteogenic directed differentiation inducing liquid further comprises sodium beta-glycerophosphate, wherein the concentration of the sodium beta-glycerophosphate is 5-10 mmol/L. For example: 5mmol/L, 6mmol/L, 7mmol/L, 8mmol/L, 9mmol/L or 10 mmol/L.
Preferably, the mesenchymal stem cell osteogenic directed differentiation inducing liquid further comprises ascorbic acid, and the concentration of the ascorbic acid is 40-50 mg/L. For example: 40mg/L, 41mg/L, 42mg/L, 43mg/L, 44mg/L, 45mg/L, 46mg/L, 47mg/L, 48mg/L, 49mg/L or 50mg/L.
Preferably, the mesenchymal stem cell osteogenic directed differentiation inducing solution further comprises dexamethasone, wherein the concentration of the dexamethasone is 0.1-0.5 [ mu ] mol/L. For example: 0.1. mu. mol/L, 0.2. mu. mol/L, 0.3. mu. mol/L, 0.4. mu. mol/L or 0.5. mu. mol/L.
Preferably, the mesenchymal stem cell osteogenic directed differentiation inducing liquid further comprises penicillin, wherein the concentration of the penicillin is 50-100U/mL. For example: 50U/mL, 60U/mL, 70U/mL, 80U/mL, 90U/mL, or 100U/mL.
Preferably, the mesenchymal stem cell osteogenic directed differentiation inducing liquid further comprises streptomycin, and the concentration of the streptomycin is 50-100 g/mL. For example: 50U/mL, 60U/mL, 70U/mL, 80U/mL, 90U/mL, or 100U/mL.
The invention further provides application of the mesenchymal stem cell osteogenic directed differentiation inducing liquid in promoting differentiation of mesenchymal stem cells into osteoblasts.
Compared with the prior art, the invention has the beneficial effects that: the inducing liquid for inducing the mesenchymal stem cells to differentiate into osteogenesis, which contains the exosomes, can obviously enhance the osteogenic differentiation efficiency of the mesenchymal stem cells, can be used for treating bone tissue regeneration and repair by the mesenchymal stem cells, enables the bone tissue regeneration and repair to differentiate directionally, and plays a role in regulating and controlling the differentiation of the mesenchymal stem cells. In addition, the mesenchymal stem cell osteogenic differentiation inducing liquid of the present invention has the following advantages:
1. the use is simple and convenient. In the process of inducing the mesenchymal stem cells to differentiate into the osteogenesis, the mesenchymal stem cells can be obviously improved by only using the mesenchymal stem cells to differentiate into the osteogenesis inducing liquid to culture the mesenchymal stem cells.
2. Is easy to prepare. The preparation method is realized by adding penicillin, streptomycin, fetal calf serum, beta-sodium glycerophosphate, ascorbic acid, dexamethasone and exosome into a commercially available alpha-MEM culture medium.
3. Exosome is easy to obtain and can be obtained by collecting cell supernatant of mesenchymal stem cells, the main extraction methods comprise an ultracentrifugation method, a gel chromatography method, an ultrafiltration method, an immunomagnetic bead method and a kit extraction method, and the prepared inducing liquid prepared by exosome can obviously improve the osteogenic differentiation efficiency of the mesenchymal stem cells.
Drawings
FIG. 1 shows the basic morphology of bone marrow mesenchymal stem cell exosomes observed under a transmission electron microscope;
FIG. 2 is a diagram showing the relationship between the activity of alkaline phosphatase in improving the differentiation efficiency of mesenchymal stem cells in a conventional osteogenesis inducing liquid and an exosome-containing mesenchymal stem cell osteogenic directed differentiation inducing liquid according to the present invention; wherein
Is a common osteogenesis inducing liquid and is characterized in that,
the invention relates to an exosome-containing mesenchymal stem cell osteogenic directional differentiation inducing liquid;
FIG. 3A is a calcium nodule staining pattern of a common osteogenesis inducing liquid for improving differentiation efficiency of mesenchymal stem cells osteoblasts;
fig. 3B is a calcium nodule staining diagram for improving mesenchymal stem cell osteoblast differentiation efficiency by the mesenchymal stem cell osteoblast directional differentiation inducing liquid according to the present invention.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
The present invention will be described in further detail below. It should be noted that the following description is only an illustration of the claimed technical solutions, and does not limit these technical solutions in any way. The scope of the present invention is defined by the appended claims.
Example 1
The embodiment provides a mesenchymal stem cell osteogenic directional differentiation inducing liquid, which comprises the following components: culture medium and exosomes.
The culture medium described in this example was an α -MEM medium.
The exosome is prepared from a culture supernatant of mesenchymal stem cells, and the final concentration of the exosome is 5-10 mg/L.
In some embodiments, the final concentration of the exosomes is 6mg/L, 7mg/L, 8mg/L, 9mg/L, or 10 mg/L.
In some embodiments, the mesenchymal stem cell osteogenic directed differentiation inducing liquid further comprises fetal bovine serum, the volume ratio of which is 5%, 6%, 7%, 8%, 9% or 10%.
In some embodiments, the mesenchymal stem cell osteogenic directed differentiation inducing liquid further comprises sodium beta-glycerophosphate, the concentration of the sodium beta-glycerophosphate being 5mmol/L, 6mmol/L, 7mmol/L, 8mmol/L, 9mmol/L or 10 mmol/L.
In some embodiments, the mesenchymal stem cell osteogenic directed differentiation inducing liquid further comprises ascorbic acid at a concentration of 40mg/L, 41mg/L, 42mg/L, 43mg/L, 44mg/L, 45mg/L, 46mg/L, 47mg/L, 48mg/L, 49mg/L or 50mg/L.
In some embodiments, the mesenchymal stem cell osteogenic directed differentiation inducing solution further comprises dexamethasone at a concentration of 0.1. mu. mol/L, 0.2. mu. mol/L, 0.3. mu. mol/L, 0.4. mu. mol/L, or 0.5. mu. mol/L.
In some embodiments, the mesenchymal stem cell osteogenic committed differentiation-inducing liquid further comprises penicillin at a concentration of 50U/mL, 60U/mL, 70U/mL, 80U/mL, 90U/mL, or 100U/mL.
In some embodiments, the mesenchymal stem cell osteogenic directed differentiation inducing liquid further comprises streptomycin at a concentration of 50U/mL, 60U/mL, 70U/mL, 80U/mL, 90U/mL, or 100U/mL.
The preparation method of the mesenchymal stem cell osteogenic directed differentiation inducing liquid comprises the following steps:
1) preparing a bone marrow mesenchymal stem cell supernatant:
adopting 2-4 generation bone marrow mesenchymal stem cells, adding 10mL culture medium containing serum into the bone marrow mesenchymal stem cells, diluting to 1 × 106Cell suspension at a concentration of 25cm3The cell culture flask of (1) was placed at 37 ℃ with 5% CO2And collecting cell culture supernatant when the culture is carried out for 36-72 h in an incubator with saturated humidity, collecting the cell culture supernatant to more than 200mL, and extracting exosome.
2) Preparing bone marrow mesenchymal stem cell exosomes:
centrifuging the supernatant at 4 deg.C and 400 Xg for 10min, transferring the supernatant, and removing cell debris; centrifuging at 4 deg.C and 2000 Xg for 10min, transferring supernatant, and removing dead cells; filtering the supernatant with 0.22 μm sterile filter membrane to further remove impurities; precipitating exosome by ultracentrifugation for 150min at 120000 Xg at 4 ℃, adding 400 mu L of PBS after removing supernatant to dissolve and collect exosome precipitate, and finally filtering by using a sterile filter membrane of 0.22 mu m so as to ensure that the purity of the obtained exosome is higher. Subpackaging in a sterile centrifuge tube, storing at-80 deg.C for use, and identifying basic form of exosome, with the result shown in FIG. 1, and FIG. 1 is basic form of exosome of mesenchymal stem cell observed under transmission electron microscope.
3. Preparation of mesenchymal stem cell osteogenic directional differentiation inducing liquid
Adding 10% fetal calf serum, 10mmol/L beta-sodium glycerophosphate, 50mg/L ascorbic acid, 0.1 mu mol/L dexamethasone and exosome with the final concentration of 5-10mg/mL into a commercially available 1L alpha-MEM culture medium to obtain the mesenchymal stem cell osteogenic differentiation inducing liquid.
Example 2
The embodiment provides application of the mesenchymal stem cell osteogenic directed differentiation inducing solution in promoting differentiation of mesenchymal stem cells into osteoblasts. The application process specifically comprises the following steps:
the umbilical cord mesenchymal cells were inoculated into an alpha-MEM culture medium containing 10% fetal bovine serum, 100U/mL penicillin and 100g/mL streptomycin, and the medium was incubated at 37 ℃ with 5% CO2Culturing in the incubator.
After the umbilical cord mesenchymal cells grow to logarithmic phase and are fused by more than 80-85%, the mesenchymal stem cell osteogenic differentiation inducing liquid is replaced by the mesenchymal stem cell osteogenic differentiation inducing liquid, and the mesenchymal stem cell osteogenic differentiation inducing liquid is replaced every three days. And culturing for 14-21 days, and analyzing the marked protein alkaline phosphatase and the marked mineralized nodules in the osteogenic differentiation process by using an alkaline phosphatase kit and alizarin red staining respectively. The results are shown in fig. 2, fig. 3A and fig. 3B, wherein fig. 2 is a graph showing the relationship between the activity of alkaline phosphatase for improving the osteoblast differentiation efficiency of mesenchymal stem cells by using the ordinary osteogenic induction liquid and the osteoblast committed differentiation induction liquid for mesenchymal stem cells containing exosomes according to the present invention; wherein
Is a common osteogenesis inducing liquid and is characterized in that,
the invention relates to an exosome-containing mesenchymal stem cell osteogenic directional differentiation inducing liquid; FIG. 3A is a calcium nodule staining pattern of a common osteogenesis inducing liquid for improving differentiation efficiency of mesenchymal stem cells osteoblasts; FIG. 3B shows the osteogenic directed differentiation of mesenchymal stem cells according to the present inventionAnd the induction liquid is used for improving the calcium nodule staining pattern of the mesenchymal stem cell osteoblast differentiation efficiency.
As can be seen from fig. 2, fig. 3A and fig. 3B, the osteogenic differentiation inducing solution for mesenchymal stem cells according to the present invention can significantly improve the osteogenic differentiation efficiency of umbilical cord mesenchymal stem cells, indicating that it can be used for umbilical cord mesenchymal stem cells to treat bone tissue regeneration and repair, and enable them to differentiate directionally.
This summary merely illustrates some embodiments which are claimed, wherein one or more of the features recited in the claims can be combined with any one or more of the embodiments, and such combined embodiments are also within the scope of the present disclosure as if they were specifically recited in the disclosure.
Claims (10)
1. The mesenchymal stem cell osteogenic directional differentiation inducing liquid is characterized by comprising the following components: culture medium and exosomes.
2. The osteogenic directed differentiation inducing solution for mesenchymal stem cells according to claim 1, wherein the culture medium is α -MEM medium.
3. The osteogenic directed differentiation inducing solution of mesenchymal stem cells according to claim 1, wherein the exosomes are prepared from a culture supernatant of mesenchymal stem cells of bone marrow, and the final concentration of the exosomes is 5-10 mg/L.
4. The mesenchymal stem cell osteogenic directed differentiation inducing liquid according to claim 1, wherein the mesenchymal stem cell osteogenic directed differentiation inducing liquid further comprises fetal bovine serum, and the volume ratio of the fetal bovine serum is 5-10%.
5. The mesenchymal stem cell osteogenic directed differentiation inducing liquid according to claim 1, wherein the mesenchymal stem cell osteogenic directed differentiation inducing liquid further comprises sodium β -glycerophosphate, the concentration of the sodium β -glycerophosphate being 5 to 10 mmol/L.
6. The mesenchymal stem cell osteogenic directed differentiation inducing liquid according to claim 1, wherein the mesenchymal stem cell osteogenic directed differentiation inducing liquid further comprises ascorbic acid, and the concentration of the ascorbic acid is 40 to 50mg/L.
7. The mesenchymal stem cell osteogenic directed differentiation inducing liquid according to claim 1, wherein the mesenchymal stem cell osteogenic directed differentiation inducing liquid further comprises dexamethasone, the concentration of which is 0.1 to 0.5 μmol/L.
8. The mesenchymal stem cell osteogenic directed differentiation inducing liquid according to claim 1, wherein the mesenchymal stem cell osteogenic directed differentiation inducing liquid further comprises penicillin, and the concentration of the penicillin is 50-100U/mL.
9. The mesenchymal stem cell osteogenic directed differentiation inducing liquid according to claim 1, wherein the mesenchymal stem cell osteogenic directed differentiation inducing liquid further comprises streptomycin at a concentration of 50-100 g/mL.
10. Use of the mesenchymal stem cell osteogenic directed differentiation inducing liquid according to claims 1 to 10 for promoting differentiation of mesenchymal stem cells into osteoblasts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910598597.7A CN112175899A (en) | 2019-07-04 | 2019-07-04 | Mesenchymal stem cell osteogenic directional differentiation inducing liquid and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910598597.7A CN112175899A (en) | 2019-07-04 | 2019-07-04 | Mesenchymal stem cell osteogenic directional differentiation inducing liquid and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112175899A true CN112175899A (en) | 2021-01-05 |
Family
ID=73914517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910598597.7A Pending CN112175899A (en) | 2019-07-04 | 2019-07-04 | Mesenchymal stem cell osteogenic directional differentiation inducing liquid and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112175899A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110212523A1 (en) * | 2008-11-11 | 2011-09-01 | Yukio Kato | Differentiation-inducing culture medium additive and use thereof |
| WO2013169202A1 (en) * | 2012-05-10 | 2013-11-14 | Biomatcell Ab | Osteogenic differentiation of mesenchymal stem cells |
| CN103667182A (en) * | 2012-12-17 | 2014-03-26 | 湖州市中心医院 | Inducing method and inducing culture medium for differentiation of bone marrow mesenchymal stem cells into osteoblasts in vitro |
| WO2014113704A2 (en) * | 2013-01-18 | 2014-07-24 | Escape Therapeutics, Inc. | Enhanced differentiation of mesenchymal stem cells |
| CN105062964A (en) * | 2015-07-17 | 2015-11-18 | 山东大学 | Inducing liquid for improving osteogenic differentiation efficiency in stem cells and application of inducing liquid |
| CN107418928A (en) * | 2017-09-05 | 2017-12-01 | 安徽瑞杰赛尔生物科技有限公司 | A kind of human mesenchymal stem cell Osteoinductive differentiation culture medium and preparation method |
-
2019
- 2019-07-04 CN CN201910598597.7A patent/CN112175899A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110212523A1 (en) * | 2008-11-11 | 2011-09-01 | Yukio Kato | Differentiation-inducing culture medium additive and use thereof |
| WO2013169202A1 (en) * | 2012-05-10 | 2013-11-14 | Biomatcell Ab | Osteogenic differentiation of mesenchymal stem cells |
| CN103667182A (en) * | 2012-12-17 | 2014-03-26 | 湖州市中心医院 | Inducing method and inducing culture medium for differentiation of bone marrow mesenchymal stem cells into osteoblasts in vitro |
| WO2014113704A2 (en) * | 2013-01-18 | 2014-07-24 | Escape Therapeutics, Inc. | Enhanced differentiation of mesenchymal stem cells |
| CN105062964A (en) * | 2015-07-17 | 2015-11-18 | 山东大学 | Inducing liquid for improving osteogenic differentiation efficiency in stem cells and application of inducing liquid |
| CN107418928A (en) * | 2017-09-05 | 2017-12-01 | 安徽瑞杰赛尔生物科技有限公司 | A kind of human mesenchymal stem cell Osteoinductive differentiation culture medium and preparation method |
Non-Patent Citations (1)
| Title |
|---|
| ""Mesenchymal stem cell transplantation in tight-skin mice identifies miR-151-5p as a therapeutic target for systemic sclerosis"", vol. 27, no. 4, pages 562 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Macrophage polarization in periodontal ligament stem cells enhanced periodontal regeneration | |
| Zhou et al. | Effect of tetrahedral DNA nanostructures on proliferation and osteo/odontogenic differentiation of dental pulp stem cells via activation of the notch signaling pathway | |
| Qi et al. | Exosomes secreted by human-induced pluripotent stem cell-derived mesenchymal stem cells repair critical-sized bone defects through enhanced angiogenesis and osteogenesis in osteoporotic rats | |
| Jing et al. | miR-381-abundant small extracellular vesicles derived from kartogenin-preconditioned mesenchymal stem cells promote chondrogenesis of MSCs by targeting TAOK1 | |
| CN110499287B (en) | Method for simply preparing placenta mesenchymal stem cell exosome | |
| CN107937342B (en) | Method for amplifying neural stem cells through endothelial cell-derived exosomes | |
| CN105209881A (en) | Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids | |
| CN113717944B (en) | miRNA13896 over-expressed engineering human umbilical cord mesenchymal stem cell source exosome and preparation method and application | |
| CN113322230B (en) | Dental pulp stem cell exosome and preparation method and application thereof | |
| CN110616190B (en) | Method for regulating and controlling periodontal ligament stem cell osteogenic differentiation based on extracellular matrix | |
| CN110478528B (en) | Preparation method and application of novel tissue repair promoting material | |
| Aly et al. | Adipose stem cells as alternatives for bone marrow mesenchymal stem cells in oral ulcer healing | |
| CN111454953A (en) | Bone marrow mesenchymal stem cell adipogenic transformation promoter | |
| CN111500578A (en) | Circ RNA-FTO for regulating and controlling osteogenic differentiation and tissue regeneration of ADSCs and application thereof | |
| CN114642630B (en) | Mineralized collagen gel loaded with gingival mesenchymal stem cell exosomes and preparation method thereof | |
| CN115478048A (en) | Preparation of exosome by culturing adipose-derived mesenchymal stem cells | |
| Chen et al. | Evaluating the defect targeting effects and osteogenesis promoting capacity of exosomes from 2D-and 3D-cultured human adipose-derived stem cells | |
| CN112175899A (en) | Mesenchymal stem cell osteogenic directional differentiation inducing liquid and application thereof | |
| CN111454896B (en) | Induction method for improving differentiation capacity of mesenchymal stem cells for promoting acute myeloid leukemia | |
| Hattori et al. | Establishment of a novel method for enriching osteoblast progenitors from adipose tissues using a difference in cell adhesive properties | |
| Li et al. | Psoralidin Induced Differentiation from Adipose-derived Stem Cells to Nucleus Pulposus-like Cells by TGF-β/Smad Signaling | |
| CN110951685A (en) | Monocyte-derived exosome preparation applied to osteogenic differentiation of mesenchymal stem cells | |
| CN114790443B (en) | Mesenchymal stem cell in-vitro culture method and culture medium thereof | |
| CN112831463B (en) | Culture medium for efficiently inducing adipose-derived stem cell bone differentiation, preparation method, induced differentiation method and application | |
| CN112522193B (en) | Application of serum-free culture medium in separation and passage of adipose-derived mesenchymal stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: Building 52, 500 Binhai East Road, Muping District, Yantai City, Shandong Province, 264199 Applicant after: Shandong Baiao Stem Cell Biotechnology Co.,Ltd. Address before: Room 402, 4th floor, building B1, standard workshop community, Xi'an Modern Textile Industrial Park, Baqiao District, Xi'an City, Shaanxi Province 710024 Applicant before: Shaanxi Baiao Stem Cell Regenerative Medicine Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: Building 52, 500 Binhai East Road, Muping District, Yantai City, Shandong Province, 264199 Applicant after: Shandong Baihong Stem Cell Biotechnology Co.,Ltd. Address before: Building 52, 500 Binhai East Road, Muping District, Yantai City, Shandong Province, 264199 Applicant before: Shandong Baiao Stem Cell Biotechnology Co.,Ltd. |